Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia

Fostamatinib demonstrated efficacy in phase 3 trials of adults with immune thrombocytopenia (ITP). Post hoc analysis compared patients who received fostamatinib as second‐line therapy (after steroids ± immunoglobulins) versus third‐or‐later‐line therapy (after ≥2 prior lines of therapy including a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Boccia, Ralph, Cooper, Nichola, Ghanima, Waleed, Boxer, Michael A, Hill, Quentin A., Sholzberg, Michelle, Tarantino, Michael D., Todd, Leslie K., Tong, Sandra, Bussel, James B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Platelets Haemostasis and Thrombosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540289/
https://www.ncbi.nlm.nih.gov/pubmed/33439486
http://dx.doi.org/10.1111/bjh.16959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540289/
https://www.ncbi.nlm.nih.gov/pubmed/33439486
http://dx.doi.org/10.1111/bjh.16959

Ejemplares similares